Literature DB >> 4026164

[Torsades de pointe. Apropos of 60 cases].

P Salle, J L Rey, P Bernasconi, J C Quiret, M Lombaert.   

Abstract

The authors report a personal series of 60 cases of "torsade de pointe" (the largest series published to date) seen in the Cardiology department of Amiens Hospital over a period of 11 years. They review the essential features of this arrhythmia, which was well described by F. Dessertenne in 1966, but which is still sometimes confused with certain forms of ventricular tachycardia. "Torsade de pointe" is still a topical issue, as 25% of the cases in this series were seen over the last two years. These cases were classified into three groups according to their aetiology: severe bradycardia (21 cases), potassium depletion (16 cases), drug causes (23 cases). This arrhythmia was essentially associated with iatrogenic factors, in particular potassium depletion (41.6% of cases). The classical notion of predisposed patients was confirmed: elderly patients (mean age of 68 years), with cardiovascular disease in 70% of cases (i.e. heart failure or coronary insufficiency, hypertension) and with a marked female predominance (70% women). The ECG between episodes of "torsade de pointe" always revealed a prolonged QT interval which, in relation to the heart rate, was more marked in the patients with potassium depletion. During an attack, the average ventricular rate was 210/min (range: 170 to 290/min). 20% of cases subsequently developed ventricular fibrillation. The overall mortality was 16.6% (10 out of 60 cases), but there have been no deaths since 1977 due to the better understanding of this arrhythmia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1985        PMID: 4026164

Source DB:  PubMed          Journal:  Ann Cardiol Angeiol (Paris)        ISSN: 0003-3928


  10 in total

Review 1.  The significance of QT interval in drug development.

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 2.  Assessing QT interval prolongation and its associated risks with antipsychotics.

Authors:  Jimmi Nielsen; Claus Graff; Jørgen K Kanters; Egon Toft; David Taylor; Jonathan M Meyer
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

Review 3.  Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 4.  Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).

Authors:  Rashmi R Shah; Joel Morganroth; Devron R Shah
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

5.  QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel.

Authors:  Judith A Martin; Anthony Campbell; Thomas Killip; Margaret Kotz; Mori J Krantz; Mary Jeanne Kreek; Brian A McCarroll; Davendra Mehta; J Thomas Payte; Barry Stimmel; Trusandra Taylor; Mark C P Haigney; Bonnie B Wilford
Journal:  J Addict Dis       Date:  2011-10

6.  Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials.

Authors:  Mitesh J Borad; Arundhati D Soman; Martin Benjamin; Daniel Casa; Waibhav D Tembe; Barbara F Piper; Ramesh Ramanathan; Raoul Tibes; Gayle Jameson; Karen Ansaldo; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2012-12-16       Impact factor: 3.850

Review 7.  Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

8.  Development of neuroleptic agents: pharmacogenetics and current safety issues of regulatory concern.

Authors:  Rashmi Shah
Journal:  Dialogues Clin Neurosci       Date:  2002-12       Impact factor: 5.986

9.  Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis.

Authors:  Antoine Poncet; Baris Gencer; Marc Blondon; Marianne Gex-Fabry; Christophe Combescure; Dipen Shah; Peter J Schwartz; Marie Besson; François R Girardin
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

10.  Management of serious cardiac adverse effects of antipsychotic medications.

Authors:  Steven C Stoner
Journal:  Ment Health Clin       Date:  2018-03-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.